OR8G5 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 could diminish OR8G5 transcription by competitively inhibiting the interaction between bromodomain-containing 4 (BRD4) proteins and acetylated histones near the OR8G5 gene, thereby reducing the recruitment of transcriptional machinery. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A has the potential to decrease OR8G5 expression by inhibiting histone deacetylases, which would maintain histones in an acetylated state, leading to a closed chromatin conformation that is less accessible for transcription at the OR8G5 locus. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could lead to the hypomethylation of CpG islands within the OR8G5 gene promoter, potentially decreasing the binding of methyl-CpG-binding domain proteins and repressive histone marks, which results in reduced transcription initiation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may attenuate OR8G5 expression by inhibiting the activity of MEK1/2, which are upstream of ERK1/2 in the MAPK pathway, thereby decreasing the phosphorylation and activation of transcription factors that normally increase OR8G5 gene expression. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516 could suppress OR8G5 expression by activating peroxisome proliferator-activated receptor delta (PPARδ), which may repress transcription factors or coactivators essential for OR8G5 gene transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin may reduce OR8G5 protein levels by inhibiting the mTOR pathway, leading to a decline in cap-dependent translation, which is crucial for the synthesis of many GPCR proteins, including OR8G5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 could curtail OR8G5 expression by inhibiting phosphatidylinositol 3-kinase (PI3K), resulting in decreased activation of AKT signaling and subsequent transcription factor activity necessary for OR8G5 gene expression. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
Wnt-C59 may inhibit the expression of OR8G5 by antagonizing Wnt/β-catenin signaling, which can result in decreased transcription of Wnt target genes, including potentially those of the GPCR family such as OR8G5. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT has the potential to decrease OR8G5 expression by inhibiting gamma-secretase activity, which is necessary for Notch receptor processing and the subsequent release of the Notch intracellular domain that can drive gene expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB 431542 may downregulate OR8G5 expression by inhibiting the transforming growth factor-beta (TGF-β) type I receptor kinase, which can lead to a decrease in SMAD phosphorylation and the nuclear translocation necessary for transcriptional responses involving GPCR genes. | ||||||